Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) i...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_wirefeeds_3039703223

Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease

About this item

Full title

Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease

Publisher

New York: Business Wire

Journal title

Business Wire, 2024

Language

English

Formats

Newsletter articles

Publication information

Publisher

New York: Business Wire

Subjects

Subjects and topics

More information

Alternative Titles

Full title

Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_wirefeeds_3039703223

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_wirefeeds_3039703223

How to access this item

Log in as a Library member

View record in ProQuest

View in old catalogue

Connecting people and collections

Indigenous engagement

Celebrating and sharing stories of Indigenous Australia, and helping to locate and prioritise Indigenous voices in the Library's collections.

Schools and teachers

Learning programs and resources linked to the curriculum.

Stories

Showcasing people, places and ideas inspired by the collection and the library community.